The goal is to minimize confounding variables and clearly distinguish the effects of each peptide in the sequence
Glucagon-like peptide 1 (GLP-1) agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists such as semaglutide and tirzepatide are approved by the United States Food and Drug Administration (FDA) for the management of obesity
Thats ok, chances are youve used medication from a compounding pharmacy before
I would also like to thank David L Ludwig for valuable discussions about the physiology and pharmacology of GLP-1 and for careful reading and commenting on the manuscript
Credentials: Board-certified Family Nurse Practitioner (FNP-BC) 10+ years of advanced practice nursing Licensed in the state of Florida Specializations: weight management, hormone therapy, urgent care, preventive medicine When You'll Visit Our Sanibel Office Most of your medical weight loss care happens virtually
Prep Smart, Eat Smarter Meal prepping ensures you have healthy options readily available